According to Ironwood Pharmaceuticals
's latest financial reports the company has $92.15 M in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $92.15 M | -85.96% |
2022-12-31 | $0.65 B | 5.82% |
2021-12-31 | $0.62 B | 71.04% |
2020-12-31 | $0.36 B | 104.81% |
2019-12-31 | $0.17 B | 2.22% |
2018-12-31 | $0.17 B | -21.79% |
2017-12-31 | $0.22 B | -27.46% |
2016-12-31 | $0.30 B | -30.54% |
2015-12-31 | $0.43 B | 76.94% |
2014-12-31 | $0.24 B | 25.67% |
2013-12-31 | $0.19 B | 17.46% |
2012-12-31 | $0.16 B | 2.57% |
2011-12-31 | $0.16 B | -33.87% |
2010-12-31 | $0.24 B | 102.79% |
2009-12-31 | $0.12 B | 36.25% |
2008-12-31 | $89.76 M | -2.36% |
2007-12-31 | $91.93 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
AstraZeneca AZN | $8.02 B | 8,603.91% | ๐ฌ๐ง UK |
Nektar Therapeutics
NKTR | $0.30 B | 229.47% | ๐บ๐ธ USA |